Medpace Holdings Inc vs Teladoc Health Inc — how do they compare? Medpace Holdings Inc trades at $614.07 (market cap $16.82B), while Teladoc Health Inc trades at $5.78 (market cap $1.01B). The key difference: Medpace Holdings Inc is far larger — about 16.7× Teladoc Health Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Teladoc Health Inc for 39 Days on average.
| MEDP | TDOC | |
|---|---|---|
Market Cap | $16.82B | $1.01B |
Volume | 223,093 | 4,668,477 |
Sector | Health | Health |
52-Week High | $630.19 | $9.72 |
52-Week Low | $393.42 | $4.47 |
Typical Hold Time | 14 Days | 39 Days |
Enterprise Value | $16.44B | $1.27B |
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Teladoc Health (TDOC) trades at $5.67, showing modest daily gains but remains near multi-year lows with a bearish technical outlook. The company maintains strong revenue around $2.5B annually but continues to report net losses, with a -7.13% net margin in 2026. Recent management changes include the appointment of a new CFO, while analyst sentiment remains cautious despite a consensus price target of $8.83 representing 56% upside potential.
TDOC presents a high-risk opportunity with significant upside potential if the company can achieve profitability turnaround. The stock trades at discounted valuations (P/S 0.4x, P/B 0.77x) but faces execution risks from ongoing losses, BetterHelp segment challenges, and potential legal investigations. Free cash flow generation and integrated care growth provide stabilization, though sustained profitability remains the key catalyst needed for sustained recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →